Genesys Capital:

Life science venture capital

We invest in early stage life science companies that are poised to change lives for the better.

About Genesys

Expertise. Experience. Insight.

Genesys Snapshot:

  • $300M+ Raised
  • $250M+ Invested
  • 5 Funds
  • 38 Companies
  • 18 Exits

Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.

Why Genesys succeeds

Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.

Stable and proven team

Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships

Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns

We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale

We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.

Our Team

Expertise. Experience. Insight.

Deep subject knowledge, Robust industry relationships, Proven insight — meet the Genesys team.

The Genesys Team

Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.

  • Jennifer Williams

    Jennifer Williams

    Director of Finance and Operations

  • Damian Lamb

    Damian Lamb

    Co-founder, Managing Director

  • Jamie Stiff

    Jamie Stiff

    Managing Director

  • Kelly Holman

    Kelly Holman

    Co-founder, Managing Director

  • Lisa Low

    Lisa Low

    Chief Financial Officer

  • Maxime Ranger

    Maxime Ranger

    Venture Partner

  • Sarah Farr

    Sarah Farr

    Associate

  • Mariya Valerova

    Mariya Valerova

    Office Manager

  • Paras Sharma

    Paras Sharma

    Associate

Our Portfolio

$250M invested
38 Companies
18 Exits

Our track record is a direct result of our approach to investment and company building.

Illumina Acquires IDbyDNA

Jun 24, 2022 - NEW YORK – Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.

Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia

Jun 13, 2022 - Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration

Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer

MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.

Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results And Clinical Program Updates

HAMILTON, Ontario & BOSTON, March 17, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2021 and provided an update on clinical and corporate developments.

Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial

MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.

Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer

FREDERICK, Md., Feb. 23, 2022 /PRNewswire/ -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.

Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update

Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications...

For older news items, visit the Genesys News Archive here

Contact us

We’re listening!

Genesys Capital is located at Front St and University Ave in downtown Toronto, in the heart of the life science hub.